Neoplasms, Plasma Cell clinical trials
The registry lists 710 studies for Neoplasms, Plasma Cell across more than 10 countries. 79 are recruiting or about to start. 90 of them are mainly about Neoplasms, Plasma Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 5 narrower conditions too, such as Multiple Myeloma: 4,467 studies, 926 open.
ClinicalTrials.gov finds 4,525 studies for Neoplasms, Plasma Cell. How that becomes 709 here
This page counts the studies the registry files under Neoplasms, Plasma Cell, and those it files under no condition that list Neoplasms, Plasma Cellthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 4,525Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −3,657Filed under a narrower condition, counted on its own pageMultiple Myeloma 3,148 · Waldenstrom Macroglobulinemia 358 · Immunoglobulin Light-chain Amyloidosis 133 · Leukemia, Plasma Cell 11 · Plasmacytoma 7
- −159Match it another way159 by a synonym or other text the search reads.
- 709The count on this page3 of them list Neoplasms, Plasma Cell in their own words; the registry filed them under no condition.
Get an email when these change. Save the Neoplasms, Plasma Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (35) · Mayo Clinic (26) · Memorial Sloan Kettering Cancer Center (22) · Fred Hutchinson Cancer Center (18) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (17) · Case Comprehensive Cancer Center (14) · H. Lee Moffitt Cancer Center and Research Institute (14) · Masonic Cancer Center, University of Minnesota (13)
What is being tested here
Drugs under test in Neoplasms, Plasma Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Drug classes tested here Corticosteroids 9 open · Proteasome inhibitors 4 open · Alkylating agents 2 open · Antimetabolites 2 open · Beta-lactamase inhibitors 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 3 · Monash University
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 3 · Monash University
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 3 · Monash University
- Mar 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) · Phase 3 · Monash University
- Apr 2027Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension · Phase 3 · Monash University
- Nov 2026Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma · University of Pennsylvania
- Nov 2026Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care · University of Miami
- Dec 2026PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study · Memorial Sloan Kettering Cancer Center
- Dec 2026PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) · Insel Gruppe AG, University Hospital Bern
- Dec 2026Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma · M.D. Anderson Cancer Center
Who these studies take
Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger. 4 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 7 (12%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (7%) | 4 (7%) |
| 18 | 53 (91%) | 53 (91%) |
| 30 | 55 (95%) | 55 (95%) |
| 40 | 56 (97%) | 56 (97%) |
| 50 | 55 (95%) | 55 (95%) |
| 65 | 56 (97%) | 56 (97%) |
| 75 | 55 (95%) | 55 (95%) |
| 85 | 40 (69%) | 40 (69%) |
Across all 710 studies, recruiting or not: 27% stop at 75 or younger and 12% at 65; 20% take children; 0% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Neoplasms, Plasma Cell studies take
Of 67 phase 2 interventional studies under Neoplasms, Plasma Cell, half reached primary completion within 58 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 60 mo27–86 · 51 studies | — | 61 mo24–96 · 35 studies |
| Phase 2 | 58 mo38–94 · 67 studies | — | 59 mo39–89 · 61 studies |
| Phase 3 | 67 mo36–97 · 19 studies | — | — |
| Interventional, no phase | 37 mo22–144 · 25 studies | — | — |
| Observational | 71 mo34–148 · 31 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Started recruiting1
Results posted1
Stopped1
- A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentTerminatedOct 28, 2026NCT04268199
Newly registered4
- A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaNov 9, 2026NCT07927023
- Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell TherapyNov 2, 2026NCT07911540
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsOct 19, 2026NCT07881835
- Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted TherapiesOct 16, 2026NCT07878208
Studies
Recruiting first, then most recently updated. Showing 50 of 710. Browse all 710 → or search them.
- A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaNot yet recruitingNCT07927023
- Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell TherapyNot yet recruitingNCT07911540Not applicable1 country
- Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell TransplantsRecruitingNCT001069251 country
- ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaRecruitingNCT06518551Phase 11 country
- Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell DisordersRecruitingNCT07075510Phase 1/21 country
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT011376431 country
- HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable1 country
- Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaRecruitingNCT04822337Phase 1/21 country
- A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple MyelomaRecruitingNCT05651932Phase 14 countries
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingNCT07881835Phase 4
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285Not applicable1 country
- Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted TherapiesNot yet recruitingNCT078782082 countries
- Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R MyelomaRecruitingNCT06066359Phase 1/21 country
- In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell NeoplasmsRecruitingNCT07586709Early Phase 11 country
- Rutgers University Study of the Genetics of Blood CancersRecruitingNCT077140441 country
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT037023091 country
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 11 country
- Faecal Microbiota Transplantation After Allogeneic Stem Cell TransplantationRecruitingNCT04935684Phase 21 country
- Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT04879043Phase 1/25 countries
- REal World MAIA UK OutcomEsNot yet recruitingNCT075324731 country
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingNCT06152575Phase 327 countries
- Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT077774061 country
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 41 country
- Delayed Toxicities Post-CAR-TRecruitingNCT076653071 country
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruitingNCT07751471Phase 21 country
- Longitudinal Data Registry of Plasma Cell DyscrasiaRecruitingNCT067600521 country
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 31 country
- CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell NeoplasmsRecruitingNCT07416682Early Phase 11 country
- Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT068707601 country
- Registry of Older Patients With CancerRecruitingNCT011378251 country
- 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Phase 2/31 country
- Evaluation of Skin Tests in Biotherapy AllergiesRecruitingNCT06971848Not applicable1 country
- A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingNCT05055063Phase 11 country
- CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell NeoplasmsRecruitingNCT07519187Early Phase 11 country
- High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell DisordersRecruitingNCT06313502Phase 11 country
- A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesRecruitingNCT07052916Not applicable1 country
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/21 country
- QLS4131 Combination Therapy in Malignant Plasma Cell NeoplasmsNot yet recruitingNCT07560449Phase 2
- Pilot Imaging Study of LeukemiaRecruitingNCT03633955Phase 11 country
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Phase 11 country
- CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic DifferentiationNot yet recruitingNCT06986434Early Phase 11 country
- Multiple Myeloma Extramedulary Disease Samples FFPENot yet recruitingNCT073545551 country
- AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH AbnormalitiesEnrolling by invitationNCT074104031 country
- Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell ImmunotherapyRecruitingNCT07390071Not applicable1 country
- Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed MyelomaRecruitingNCT06947083Phase 21 country
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)RecruitingNCT07202091Phase 2/31 country
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)RecruitingNCT07202052Phase 2/31 country
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)RecruitingNCT07202078Phase 2/31 country
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)RecruitingNCT07202065Phase 2/31 country
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaRecruitingNCT07106671Phase 21 country